Chemical Restraint: CMS Rules and Compliance

Compliance note: This guide provides administrative and regulatory compliance information based on federal standards published by CMS and The Joint Commission. It is intended solely for healthcare administrators, risk managers, and compliance officers. It does not provide medical advice, diagnosis, or patient-specific treatment instructions.

What It Is and Who Runs It

In healthcare administration, a chemical restraint is the administration of a medication to manage a patient’s behavior or restrict their freedom of movement when that medication is not a standard treatment or dosage for the patient’s condition. Unlike standard pharmacotherapy aimed at treating diagnosed pathophysiology, chemical restraint is regulated as a coercive behavioral restriction.

The regulatory framework governing chemical restraint in the United States is established and enforced by two primary bodies:

Centers for Medicare & Medicaid Services (CMS): An operating division of HHS setting binding Conditions of Participation (CoP) for acute care hospitals under 42 CFR § 482.13 and long-term care facility rules under 42 CFR Part 483. CMS enforces compliance through State Survey Agencies using the CMS State Operations Manual (SOM).
The Joint Commission (TJC): An independent healthcare accrediting organization. TJC enforces restraint standards in its Comprehensive Accreditation Manual for Hospitals (CAMH) under Provision of Care Standard PC.03.05.01.

Together, these authorities enforce federal oversight across inpatient facilities. For related standards on physical devices, see our guide on medical restraints.

Scope and Regulatory Applicability

Federal restraint standards apply across Medicare- and Medicaid-certified healthcare settings, including:

Acute care inpatient hospitals: Governed by 42 CFR § 482.13(e), encompassing emergency departments, intensive care units, and medical-surgical floors.
Inpatient psychiatric facilities: Governed by 42 CFR § 482.60 alongside baseline hospital Conditions of Participation.
Critical access hospitals (CAHs): Regulated under 42 CFR § 485.635 patient rights provisions.
Skilled nursing facilities (SNFs): Governed by 42 CFR § 483.10(e) and § 483.12, where chemical restraints face survey scrutiny under CMS F-Tag F605.

Across covered facilities, patients possess a legally protected right to be free from restraints imposed for discipline or staff convenience.

Regulatory Requirements and the Two-Prong Test

The federal statutory definition of a restraint is codified at 42 CFR § 482.13(e)(1)(i)(B) as:

“A drug or medication when it is used as a restriction to manage the patient’s behavior or restrict the patient’s freedom of movement and is not a standard treatment or dosage for the patient’s condition.”

In CMS State Operations Manual Appendix A (Tags A-0154 and A-0155), CMS outlines the two-prong test. For a medication administration to be classified as a chemical restraint, both prongs must be met:

Behavioral restriction prong: The medication is used to restrict freedom of movement or manage behavior.
Non-standard treatment prong: The medication or dosage is not a standard treatment for the patient’s diagnosed condition.

If only one prong is met, the medication is not a chemical restraint under federal rules. Administering therapeutic doses of anxiolytics or antipsychotics to treat diagnosed psychiatric illness or alcohol withdrawal constitutes standard medical treatment. Administering a sedative primarily to subdue an agitated patient for ward convenience satisfies both prongs and constitutes an impermissible restraint.

Under 42 CFR § 482.13(e)(5), restraints may never be used for coercion, discipline, convenience, or retaliation. For broader operational context, review our guide to restraint and seclusion under the CMS Conditions of Participation.

Clinical Compliance Steps and Documentation

When an acute situation escalates and medication is considered for behavioral management, clinical teams must complete this mandatory compliance sequence:

Exhaust and Document Less Restrictive Alternatives: Staff must attempt non-pharmacological interventions, including verbal de-escalation, sensory reduction, and environmental adjustments. Charting must identify the specific measures attempted and why they failed.
Obtain an Individualized Prescriber Order: Restraints require an explicit order from a physician or authorized licensed practitioner (42 CFR § 482.13(e)(6)). Standing or PRN (“as needed”) orders for chemical restraints are strictly prohibited.
Conduct the Face-to-Face Evaluation: In violent or self-destructive behavioral emergencies, a physician or authorized practitioner must conduct an in-person clinical evaluation within 1 hour of initiation.
Execute Continuous Clinical Monitoring: Staff must monitor airway patency, respiration, vital signs, and cognitive responsiveness at regular intervals.
Ensure Early Discontinuation: Restraint must be discontinued at the earliest possible time once the imminent safety threat ceases (42 CFR § 482.13(e)(2)).

Governance protocols must align with baseline patient rights outlined in our reference on informed consent.

Typical Timeline Phases and Monitoring

Compliance workflows follow strict chronological phases from initial acute distress through post-intervention review, as described in official CMS interpretive guidelines on 2026-11-07:

Phase 1: Emergent De-Escalation (Minutes 0–15): Staff identify escalating agitation, apply verbal de-escalation, and remove hazards. If de-escalation fails and immediate physical danger persists, the prescriber is contacted.
Phase 2: Order Issuance and Time Limits: The prescriber issues a time-limited order. Behavioral emergency orders cannot exceed 4 hours for adults aged 18 and older, 2 hours for ages 9–17, and 1 hour for children under 9.
Phase 3: Active Monitoring: Nursing staff conduct continuous observation, recording vital signs and physiological status at designated institutional intervals.
Phase 4: Discontinuation and Debriefing (Within 24 Hours): The restraint terminates immediately upon behavioral resolution. Within 24 hours, clinical staff conduct a debriefing with the patient to review triggers and amend the care plan.

Common Compliance Mistakes

CMS hospital surveys and Joint Commission audits frequently cite these recurring deficiencies:

Authorizing PRN Restraint Orders: Prescribing sedatives as PRN for behavioral management. CMS Tag A-0155 strictly forbids PRN restraint orders.
Confusing Standard Sedation with Chemical Restraint: Mislabeling emergency behavioral restraints as routine medication, or logging standard procedural sedation as restraint.
Incomplete De-Escalation Records: Documenting agitation without recording specific non-pharmacological interventions attempted prior to medication.
Missing the 1-Hour Face-to-Face Evaluation: Failing to complete and document the required in-person evaluation within 60 minutes for behavioral emergencies.
Failing to Discontinue Promptly: Retaining restraints until order expiration rather than ending the intervention immediately when danger resolves.
Overlooking Seating Restrictions: Failing to identify when physical chairs create concomitant restraint conditions, as analyzed in our review of geriatric chair regulatory classifications.

Facilities should audit restraint practices regularly following established OIG compliance program guidance.

The regulatory requirements governing behavioral restraints across different settings are summarized below:

Regulatory Framework	Governing Authority	Primary Standard	Core Operational Requirements	Enforcement Mechanism
Hospital Conditions of Participation	CMS / HHS	42 CFR § 482.13(e)	Two-prong test; ban on PRN orders; 1-hour face-to-face evaluation for violent behavior; time-limited orders; least restrictive hierarchy.	CMS SOM surveys; Form CMS-2567 deficiency notices; loss of Medicare certification.
Long-Term Care Requirements	CMS / HHS	42 CFR § 483.10(e) & § 483.12	Freedom from chemical restraints; psychotropic stewardship; mandatory Gradual Dose Reduction (GDR).	Annual health inspection surveys; CMS F-Tag citations (F605, F758); civil money penalties.
Hospital Accreditation Standards	The Joint Commission	CAMH PC.03.05.01	Restraint restricted to imminent physical safety threats; documented alternative failure; time-limited orders.	Accreditation surveys; Requirement for Improvement (RFI); conditional accreditation status.
Critical Access Hospital CoP	CMS / HHS	42 CFR § 485.635	Hospital-level patient rights and restraint protections adapted for rural facilities.	State survey agency inspections and deemed-status surveys.

Frequently Asked Questions

What does “chemically sedated” mean?

“Chemically sedated” describes a clinical state of reduced consciousness, drowsiness, or calm induced by medication. It is a standard physiological effect used in routine medical procedures such as surgical anesthesia, endoscopy, and intensive care mechanical ventilation. In contrast to chemical restraint, standard chemical sedation is delivered to enable therapeutic care, not to manage behavior or restrict movement.

What is the definition of a restraint according to the CMS Regulation?

Under CMS regulation 42 CFR § 482.13(e)(1)(i)(B), a restraint is defined as any drug or medication when it is used as a restriction to manage the patient’s behavior or restrict the patient’s freedom of movement and is not a standard treatment or dosage for the patient’s condition. CMS applies a two-prong test requiring both behavioral restriction and non-standard treatment or dosage.

What is classed as a chemical restraint?

No medication is inherently classed as a chemical restraint based solely on its pharmacological class. Any medication—including antipsychotics, benzodiazepines, or sedatives—is classed as a chemical restraint when administered to restrict freedom of movement or control behavior outside accepted standard clinical treatment for the patient’s diagnosed condition.

Is Ativan a chemical restraint?

Ativan (lorazepam) is not inherently a chemical restraint. When administered at standard dosages to treat diagnosed medical conditions—such as alcohol withdrawal, acute anxiety, or status epilepticus—it represents standard therapeutic treatment. It is classed as a chemical restraint only if administered primarily to suppress or immobilize a patient’s behavior outside established clinical indications.

Are PRN orders permitted for chemical restraints under CMS rules?

No. Under CMS Conditions of Participation (42 CFR § 482.13) and Joint Commission standards (PC.03.05.01), standing or PRN (“as needed”) orders for chemical restraints are strictly prohibited. Each administration requires an individualized prescriber assessment and a time-limited clinical order.

Sources

Centers for Medicare & Medicaid Services (CMS). 42 CFR § 482.13 – Condition of Participation: Patient’s Rights. Electronic Code of Federal Regulations (eCFR). As described on the official page on 2026-11-07. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-482/subpart-B/section-482.13
Centers for Medicare & Medicaid Services (CMS). State Operations Manual (SOM), Appendix A – Survey Protocol, Regulations and Interpretive Guidelines for Hospitals (Tags A-0154, A-0155, A-0168). As described on the official page on 2026-11-07. https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/som107ap_a_hospitals.pdf
Centers for Medicare & Medicaid Services (CMS). 42 CFR § 483.10 and § 483.12 – Requirements for States and Long Term Care Facilities: Resident Rights and Freedom from Abuse, Neglect, and Exploitation. Electronic Code of Federal Regulations (eCFR). As described on the official page on 2026-11-07. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-483/subpart-B/section-483.10
The Joint Commission. Comprehensive Accreditation Manual for Hospitals (CAMH), Standard PC.03.05.01: Restraint and Seclusion Standards. As described on the official page on 2026-11-07. https://www.jointcommission.org/